Study: More men are investing in high-end skin care products
PORT WASHINGTON, N.Y. — Sales of men’s skin care products are on the rise as men grow increasingly concerned with looking good from head to toe and show a willingness to invest in high-end skin care, according to recent research by market research firm the NPD Group.
On track with the sales in the men’s current retail business, men’s skin care sales increased 6% year-to-date (January through July) 2012, compared with the same time last year, generating $45.5 million. In addition, NPD found that at least seven out of 10 men are buying facial skin care products for themselves.
“The growth in men’s skin care sales echoes the strong performance in the overall prestige beauty market,” stated Karen Grant, VP and senior global industry analyst for The NPD Group. “As seen in many beauty departments, products like facial moisturizers and eye treatments can be found next to the basic bar soap and shaving cream.”
All men’s segments posted increases in dollars in the first seven months of the year, versus January through July of 2011, with four exceeding the overall category performance: Sets and kits (up 11%), body (up 14%), sun (up 27%) and hair (up 8%). Face was the only category that did not outperform the total, but captured the lion’s share of the men’s business, totaling 81% dollar share. The face segment generated $36.7 million and increased 5% year-to-date 2012.
“Many men are catching up to women with embracing the routine of a facial skin care regimen. The double-digit increase in sets and kits, which are often introductory products, is quite promising leading us to believe that more and more men are conquering the facial skin care frontier,” stated Grant.
Among the top 10 men’s sub-segments, six outperformed the category: facial moisturizers (up 7%), eye treatment (up 16%), all other body (up 13%), body cleansers (up 16%), and all other face (up 30%). For the first time in the last four years, the sub-segment of age specialist declined in both dollar (down 21%) and unit growth (down 25%).
The overall best-selling men’s skincare products for year-to-date 2012 were Clinique’s Skin Supplies for Men Face Scrub 3.4 oz., followed by Skin Supplies for Men: Lotion tube, another Clinique best seller.
“With substantial growth in a number of smaller categories, it seems that men are stepping out of their comfort zone even further to try the latest skincare innovations,” added Grant. “Men are purchasing toners and clarifiers to brightening specialists and ‘In Sun’ protection products, making it quite an interesting time for men’s grooming products.”
FDA gives Wockhardt tentative approval for bipolar, schizophrenia drug
PARSIPPANY, N.J. — Indian drug maker Wockhardt has received tentative approval from the Food and Drug Administration for a generic version of a Pfizer psychiatric drug.
Wockhardt announced the tentative approval for ziprasidone hydrochloride in the 20 mg, 40 mg, 60 mg and 80 mg strengths, used to treat bipolar disorder and schizophrenia, and the company plans to launch the drug on Sept. 2, 2012.
The drug is a generic version of Pfizer’s Geodon, which has a market size of about $1.3 billion, according to IMS Health. Tentative approval means that the generic drug meets the conditions for FDA approval, but the agency can’t approve it because the branded drug’s patent has not yet expired. One of Geodon’s patents expired in March 2012, and another expires on Sept. 1 of this year, while two more expire in 2018 and 2019, according to FDA records. The drug will lose data exclusivity in November 2012.
AcelRx starts third phase-3 trial of drug for post-operative pain
REDWOOD CITY, Calif. — A drug maker that specializes in pain medications started the third late-stage trial of a drug for treating pain in patients who have undergone certain surgeries.
AcelRx Pharmaceuticals announced the dosing of the first patient in a phase-3 trial of ARX-01 (sufentanil), also called the Sufentanil NanoTab PCA System, a patient-controlled analgesic therapy designed to be placed under the tongue in patients who have undergone hip or knee-replacement surgery. The drug is designed as an alternative to treatments that involve intravenous pumps delivering morphine.
"The start of our third phase-3 clinical trial for ARX-01 is an important milestone for our lead sufentanil NanoTab development program," AcelRx president and CEO Richard King said. "The results of all three phase-3 registration studies are expected to form the basis of a new drug application for ARX-01, which we plan to submit to the [Food and Drug Administration] during the third quarter of 2013."
The study will enroll approximately 400 patients, who will receive either Sufentanil NanoTabs or placebo NanoTabs.